Issue link: https://www.e-digitaleditions.com/i/1543258
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. Inhalation February 2026 35 SPECIAL SECTION Formulation Development/Excipients This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. Comprehensive formulation services for inhaled and nasal drug delivery Bespak, the specialist inhalation CDMO, draws on decades of experience to streamline device and drug-device product development for inhaled and nasal delivery. With expertise spanning formats including pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers (SMIs), and unit-dose and multi-dose nasal sprays, Bespak accelerates your product from concept to commercial delivery. e company provides tailored end-to-end services encompassing regulatory support and analyt- ical expertise for API characterization, formulation, and stability testing for solutions, suspensions and dry powder blends. With SMI technology suitable for delicate biologics and state-of-the-art facilities sup- porting scalable low-carbon pMDI production with next-generation propellants, Bespak can streamline your journey to market. Bespak UK: +44 1477 537112 enquiries@bespak.com www.bespak.com Integrated solutions for pulmonary and nasal delivery With 30+ years' experience in pulmonary and nasal delivery, Catalent offers integrated solutions with clinical- to commercial-scale development and man- ufacturing capabilities for spray-dried or micronized dry powders for inhalation, capsules for inhalation and unit-dose, bi-dose and multi-dose nasal liquid and powder products, including sterile vials for neb- ulization of small molecules and biopharmaceuticals. In addition, Catalent provides comprehensive ana- lytical and clinical supply services to support your molecule from development through product launch and beyond. With state-of-the-art facilities in Boston, Massachusetts and Morrisville, North Carolina, US, Catalent can handle the most complex projects and help bring your inhaled therapy to market, faster. Catalent US: +1 888 SOLUTION (765-8846) solutions@catalent.com www.catalent.com